Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet (London, England) · 2021
   Trial
2. From Tumour to Bloodstream: Advancing PD-L1 Testing With Liquid Biopsies in Non-Small Cell Lung Cancer.Cytopathology : official journal of the British Society for Clinical Cytology · 2026
   Review
3. Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma.Nature cancer · 2025
   Article
4. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.Nature reviews. Cancer · 2024
   Review
5. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.Frontiers in medicine · 2024
   Review
6. Research square · 2023
   Article
7. PD-L1, a Master Regulator of Immunity 2.0.International journal of molecular sciences · 2023
   Article
8. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.Cancers · 2022
   Review
9. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.Current oncology (Toronto, Ont.) · 2022
   Review
10. The current state of molecular profiling in gastrointestinal malignancies.Biology direct · 2022
    Review
11. Preclinical antibody-PET imaging of PD-L1.Frontiers in nuclear medicine · 2022
    Review
12. Immunotherapy in Lung Cancer: Current Landscape and Future Directions.Frontiers in immunology · 2022
    Review

Corrections and comments

• Comment on
  Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.